2.  

U.S. House, Committee on Government Operations, Use of Advisory Committees by the Food and Drug Administration, 11th report, based on a study by the Intergovernmental Relations and Human Resources Subcommittee, 94th Cong., 2nd Sess., Report No. 94-787 (January 26, 1976).

3.  

Stockman, Paul K, Applicability of the Federal Advisory Committee Act to Alternative Sources of Scientific Input, report to the IOM FDA advisory committee study (July 31, 1992).

4.  

Department of Health, Education, and Welfare. Review Panel on New Drug Regulation: Final Report (Washington, D.C., May 1977).

5.  

Commission on the Federal Drug Approval Process, Final Report (Washington, D.C., March 31, 1982).

6.  

President's Cancer Panel, National Committee to Review Current Procedures for Approval of New Drugs for Cancer and AIDS. (Washington, D.C., August 15, 1990).

7.  

U.S. Department of Health and Human Services. Final Report of the Advisory Committee on the Food and Drug Administration (Washington, D.C., May 1991).

8.  

Council on Competitiveness. Fact Sheet: Improving the Nation's Drug Approval Process (Washington, D.C., 1991).

9.  

Kutak Rock & Campbell. FDA Safeguards Against Improper Disclosure of Financially-Sensitive Information (Washington, D.C., November 1991).

10.  

Ibid., p. 69.



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement